

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Hughes  
Customer No.: 51957  
Serial No.: Applied for

Filed: Submitted herewith

For: METHODS AND COMPOSITIONS  
FOR THE INTRAVENOUS  
ADMINISTRATION OF COMPOUNDS  
RELATED TO PROTON PUMP  
INHIBITORS

Examiner: Not Known  
Group Art Unit: Not Known

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Applicant provides with regard to the above-identified patent application entitled METHODS AND COMPOSITIONS FOR THE INTRAVENOUS ADMINISTRATION OF COMPOUNDS RELATED TO PROTON PUMP INHIBITORS, documents of which he is aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of the documents submitted is set forth on the attached Information Disclosure Citation (Form PTO-1449).

While these documents may be material pursuant to 37 C.F.R. §1.56, the disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be

construed to mean that a search has been conducted or that no other material documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,

/Brent A. Johnson/

Date: August 8, 2006

---

Brent A. Johnson  
Patent Agent  
Registration Number 51,851

Please direct all inquiries and correspondence to:

Brent A. Johnson  
Allergan, Inc.  
2525 Dupont Drive, T2-7H  
Irvine, California 92623-9534  
Tel: (714) 246-4348  
Fax: (714) 246-4249

FILED ELECTRONICALLY

**LIST OF ART CITED BY APPLICANT**

ATTY. DOCKET: 17627AP )	SERIAL NO.: Applied for
APPLICANT: Hughes	TITLE: METHODS AND COMPOSITIONS FOR THE INTRAVENOUS ADMINISTRATION OF COMPOUNDS RELATED TO PROTON PUMP INHIBITORS
FILING DATE: Applied for	GROUP: Not Known

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	4,045,563	8/30/1977	Berntsson et al			
	AB	4,255,431	3/10/1981	Junggren et al			
	AC	4,628,098	12/9/1986	Nohara et al			
	AD	4,686,230	8/11/1987	Rainer et al			
	AE	4,758,579	7/19/1988	Kohl et al			
	AF	4,965,269	10/23/1990	Brandstrom et al			
	AG	5,021,433	6/4/1991	Alminger et al			
	AH	5,708,017	1/13/1998	Dave et al			
	AI	5,430,042	7/4/1995	Lindberg			
	AJ	5,693,818	12/2/1997	Von Unge			
	AK	6,369,085	4/9/2002	Cotton et al			
	AL	5,045,552	9/3/1991	Souda et al			
	AM	6,093,734	7/25/2000	Garst et al			
	AN	6,897,227	5/24/2005	Garst et al			
	AO	2005/0038076	2/17/2005	Garst et al			
	AP	6,559,167	5/6/2003	Garst et al			
	AQ	2005/0075371	4/7/2005	Shen et al			

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	AS	WO 00/09498	2/24/2000	PCT			
	AT	WO 02/30920	4/18/2002	PCT			
	AU	WO 02/00166	1/3/2002	PCT			

EXAMINER \_\_\_\_\_ DATE CONSIDERED \_\_\_\_\_  
\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF ART CITED BY APPLICANT**

ATTY. DOCKET: 17627AP )	SERIAL NO.: Applied for
APPLICANT: Hughes	TITLE: METHODS AND COMPOSITIONS FOR THE INTRAVENOUS ADMINISTRATION OF COMPOUNDS RELATED TO PROTON PUMP INHIBITORS
FILING DATE: Applied for	GROUP: Not Known

**OTHER REFERENCES**  
(Including Author, Title, Date, Pertinent Pages, etc.)

AV	Design of Prodrugs (Bundgaard H. ed.) 1985 Elsevier Science Publishers B. V. (Biomedical Division), Chapter 1; Design of Prodrugs: Bioreversible derivatives for various functional groups and chemical entities (Hans Bundgaard)
AW	Bundgaard et al. Int. J. of Pharmaceutics 22 (1984) 45-56 (Elsevier)
AX	Bundgaard et al. Int. J. of Pharmaceutics 29 (1986) 19-28 (Elsevier)
AY	Bundgaard et al. J. Med. Chem. 32 (1989) 2503-2507
AZ	Chem. Abstracts 95, 138493f (Bundgaard et al.)
BA	Chem. Abstracts 95, 138592n (Bundgaard et al.)
BB	Chem. Abstracts 93, 137935y (Bundgaard et al.)
BC	Chem. Abstracts 110, 57664p (Alminger et al.)
BD	Chem. Abstracts 115, 64029s (Buur et al.)
BE	Chem. Abstracts 115, 189582y (Hansen et al.)
BF	Chem. Abstracts 117, 55790x (Jensen et al.)
BG	Chem. Abstracts 123, 17593b (Thomsen et al.)
BH	Sih., et al. (Journal of Medicinal Chemistry, 1991, vol. 34, pp 1049-1062)
BI	Handbook On Injectable Drugs (11th edition), edited by Lawrence A. Trissel, (Chicago: Login Brothers Book Company; January 15, 2001).
BJ	<a href="http://www.astazeneca.co.uk/downloads/LosecInfusion(9476).pdf">http://www.astazeneca.co.uk/downloads/LosecInfusion(9476).pdf</a>

EXAMINER \_\_\_\_\_

DATE CONSIDERED \_\_\_\_\_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.